Back To Search Results

Beta Thalassemia Major (Cooley Anemia)

Editor: Hira Shaikh Updated: 9/15/2023 6:12:56 PM


Thalassemia and sickle cell disease are some of the most common single-gene inherited hemoglobin disorders worldwide. Unlike sickle cell disease, which is a qualitative globin chain defect, thalassemia results from quantitative defects (beta+ and beta0) in one or more globin chains of hemoglobin and causes hypochromic microcytic anemia. Dr. Cooley was the first to report beta-thalassemia in Detroit in 1925, hence coined the name Cooley anemia. It is more prevalent in Mediterranean descent, Middle Eastern, and Asian populations. It was hypothesized that it started off in the United States, not in the Mediterranean because the clinical features were cloaked by malaria, which has a similar presentation. In contrast, Central Africa was the origin of sickle cell disease. Due to changing demographics, these two diseases are now major health concerns around the globe. The thalassemia disease varies both genotypically and phenotypically due to the detection of more than 200 globin gene mutations so far. Based on clinical and laboratory findings, thalassemia has been classified into three main types, which include beta-thalassemia minor, beta-thalassemia intermedia, and beta-thalassemia major (homozygous condition). Based on severity, the thalassemia intermedia and thalassemia major (TM) are further classified into transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) respectively. The spectrum of severity ranges from mild anemia to moderate and severe anemia. Its clinical features include severe hemolytic anemia, bone abnormalities, and hepatosplenomegaly (HSM).[1][2][3][4]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


Beta-thalassemia is a hereditary disorder that is caused by more than 200 beta-globin gene point mutations resulting in decreased or absent globin chains (beta+ and beta0) via transcriptional, translational, and splicing of either the hemoglobin subunit beta (HBB) itself or its product. It can also be caused by HBB gene deletion from chromosome 11. The majority of the mutations result in frameshift due to deletion, single nucleotide substitution, and insertion patterns. Furthermore, the disease severity depends on the inheritance of two copies of both alleles present on each chromosome 11. The beta-globin chain production is genotypically allocated by beta+ and beta 0 for decreased production and absent production, respectively. While phenotypic variability is represented by minor or trait, intermedia, and major, it depends on the beta-globin gene production (i.e., beta+ and beta 0) and homozygous or heterozygous status.[2][5]


Due to changing demographics, beta-thalassemia is present globally. However, it is most prevalent in the Mediterranean, Middle East, Southeast & South Asia, and southern China. The incidence of children born with beta-thalassemia major is about 68,000 worldwide. The prevalence rate is 1.5% (80-90 million carriers) across the globe. The exact prevalence rate in the United States (US) is not known, however, it is speculated that the number is increasing dramatically due to immigration. In 1960, the prevalence rate was 5.6%, and it reached 13% in 2010, which was highest in California due to 26% of immigrant residents. The highest prevalence (10%) is present in the southern and northern parts of Iran in close proximity to the Persian Gulf and the Caspian Sea, respectively. The total estimation for homozygotes is 20,000, and the carriers are approximately 3,750,000 there. In India, about 10,000-20,000 children are born with beta-thalassemia every year. The incidence of beta-thalassemia major (beta-TM) positive newborns was significantly reduced from 272/year in 2002 to 25/year in 2010 due to the introduction of a premarital screening test. In Bangladesh, the prevalence of thalassemia with different severity levels ranges from 60,000 to 70,000 with an estimated 2500 TM cases added per year. One of the proposed reasons for the high prevalence rate among the above-mentioned territories is that they are malaria-endemic regions that have a survival advantage due to a protective phenomenon. The other contributing factor is genetic drift.[2][3][6][7][8][9][10]


Hemoglobin is a tetramer formed from two dimers of alpha and non-alpha chains. Adult hemoglobin (HbA or HbA1) comprised of two alpha and two beta globin chains account for 98% of total hemoglobin. The other type is HbA2, which is made up of two alpha and two delta chains. Another type is fetal hemoglobin (HbF), which is present during pregnancy and up to 6 months postpartum and is made of two alpha and two gamma chains.

The primary underlying pathophysiology in thalassemia is ineffective erythropoiesis. It is characterized by decreased HbA production secondary to decreased beta-globin chain production and maturation arrest due to apoptosis of the erythroid precursors caused by an excess of alpha chain precipitates. Another mechanism that plays an important role is oxidative stress. Normally the balance is maintained between antioxidants like reduced glutathione and reactive oxygen species (ROS), a byproduct of cellular respiration, for maintenance of the physiologic environment. In beta-thalassemia, oxidative stress ensues due to the failure of that balance, which results in damage to the red blood cell (RBC) membrane causing anemia, white blood cells (WBC) causing infections, platelets causing hypercoagulability, and affecting other organs as well.[11][12]

History and Physical

Patients with thalassemia minor/trait are usually asymptomatic or present with mild anemia. The presentation of thalassemia intermedia varies clinically and is manifested by pallor, failure to thrive (FTT), lethargy, and fatigue, but they are not transfusion dependent.

Usually, patients with beta TM (Cooley anemia) start having symptoms after 6 months of age due to the transition of HbF to HbA. Unlike thalassemia minor, clinical features of beta TM are of a severe type and include pallor, shortness of breath, irritability, FTT, and hepatosplenomegaly (HSM) due to extramedullary hematopoiesis. Other features include recurrent fever, feeding problems, and abdominal distention. Patients who are either untreated or received poor transfusion (especially in developing countries where there is no availability of well-developed transfusion programs) develop a wide range of symptoms such as retarded growth, brown discoloration of the skin, jaundice, leg ulcers, knock knee (genu valgum), and skeletal deformities such as long bone abnormalities, craniofacial deformities like frontal bossing, prominent cheekbones, depressed nasal bridge, and maxillary hypertrophy resulting from bone marrow expansion giving the chipmunk appearance. In addition to that, gallstone formation usually occurs due to chronic hemolysis.[2][13][14]


In infants and children under 2 years of age, the diagnosis of Cooley anemia (beta TM) is suspected based on clinical features of jaundice, severe hypochromic microcytic anemia, and HSM.

Lab findings: CBC will show microcytic anemia with decreased Hb level of <7g/dL, mean corpuscular volume (MCV) ranges from 50 to 70 fl, and mean corpuscular Hb (MCH) level ranges from 12 to 20pg.

Morphological changes of RBCs like microcytosis, hypochromia, poikilocytosis, anisocytosis, and nucleated RBCs can be seen on the peripheral blood smear. Additionally, target cells, teardrop cells, and basophilic stippling (course type) can also be visualized on the peripheral blood smear. The number of erythroblasts depends on the degree of anemia and after splenectomy. Moreover, either Hb electrophoresis or high-performance liquid chromatography (HPLC) is warranted for definitive diagnosis. It analyzes Hb both quantitatively and qualitatively. Beta-thalassemia major demonstrates a complete absence of beta-globin chain (beta0/beta0), therefore the HbF is 92% to 95%, HbA2 is 5% to 8%, and HbA 0%.

Elevated HbA2 is also caused by hyperthyroidism, vitamin B12 and folic acid deficiency, and anti-retroviral therapy (ATT). Apart from that, prenatal screening and genetic counseling are additional valuable tools in the detection and prevention of beta-thalassemia and other autosomal recessive diseases.  

Radiographic features:  Due to active bone marrow hyperplasia, wide medullary spaces, and trabeculae mimic, a classic “chicken wire” pattern is seen on maxillofacial radiographs. On x-rays of long bones, osteopenia, and cortical thinning secondary to expanded bone marrow spaces can be seen, which often presents with pathological fractures. Similarly, the classic “hair on end” appearance can be seen on a cranial vault radiograph. Additionally, vertebral bodies have a ground-glass appearance. Magnetic resonance imaging (MRI) of the brain, heart, and liver are also done to determine iron deposition in various tissues in cases of suspected iron overload.[2][13][14][15]

Treatment / Management

Medical TreatmentBlood transfusion has been the mainstay treatment of beta-thalassemia major (Cooley anemia). Usually, the patient dies before reaching puberty if he/she does not receive periodic blood transfusions. It provides normal RBCs that compensate for anemia, halts ineffective erythropoiesis, which results in decreased oxidative stress, thus reducing bone deformities, improved symptoms, and increased survival. There is general consensus between the Thalassemia International Federation (TIF) and other national guidelines (the United Kingdom and the United States) about thalassemia management despite few differences in terms of iron overload (IO) and iron chelation therapy (ICT) strategies.

The degree of anemia and/or clinical findings should be considered when the frequency of blood transfusions is decided, and leukoreduced RBCs are preferred. To accelerate growth and minimize symptoms, the pretransfusion goal Hb level is 9-10g/dL or if clinical complications are present irrespective of Hb level, and the post-transfusion is between 14-15g/dL. A higher pretransfusion level of 10-12g/dL is set in cases of a worsening of extramedullary hematopoiesis or cardiac abnormalities. However, care should be taken during regular blood transfusion because of the high risk of iron overload (IO), infections, transfusion reactions, and allogeneic antibody formation.

Clinical features and serum ferritin are reliable tools in close monitoring for IO in routinely transfused TM patients. Iron chelation therapy (ICT) is the treatment of choice for iron overload. Deferoxamine was the first to be used via subcutaneous (SC) or intravenously (IV) route over 8 to 24 hrs, 5 to 7 nights/week. Compliance was the main issue with deferoxamine. Currently, oral ICT such as deferasirox or deferiprone is widely used either alone or in combination and is well tolerated. Due to rapid cell turnover, other nutritional deficiencies such as folate/vitamin B12, and calcium need to be addressed as well.

No added benefit of hydroxyurea has been established in patients receiving adequate blood to achieve the pretransfusion goal. Unlike sickle cell disease (in which it reduces sickling by increasing HbF level), the role of hydroxyurea is unclear in Hb <9 g/dL.

The only definitive treatment at present is allogeneic hematopoietic stem cell transplant (allo-HSCT) in transfusion dependant patients with >90% success rate if it takes place before the IO-related damage occurs. 

Luspatercept: Luspatercept is an erythroid maturation agent that has been approved for anemia in adult beta TM patients who require regular blood transfusions. Recently an open-label phase 3 study (BELIEVE) of adult thalassemia patients, luspatercept has yielded promising results in terms of transfusion independence. 

Gene therapy: This is also in the pipeline to be considered as a potential cure for beta-thalassemia and sickle cell disease (SCD). Several clinical trials are currently underway to establish its efficacy and safety. However, preliminary results of one of the recent ongoing trials have been promising. A total of 3 beta-thalassemia patients (n=3) have been transduced with autologous CD34 HSCs using GLOBE or TNS9.3.55 as lentivirus and have demonstrated minimal and reversible adverse effects. However, to further validate its efficacy and safety, more data is warranted.

Surgical treatment: TM patients can develop hypersplenism and massive splenomegaly, therefore, they require splenectomy as well as vaccination against encapsulated bacteria due to the high risk of infections following splenectomy.

Prevention: Currently implementation of prevention strategies is required to prevent new cases particularly in developing countries where there is limited access to standard medical treatment in addition to high consanguinity practice in the communities. Molecular diagnostics, genetic counseling, carrier detection, and prenatal screening are important tools of comprehensive preventive programs.[2][16][17][18]

Differential Diagnosis

Some of the close differentials are sideroblastic anemia, iron-deficiency anemia (IDA), and anemia of chronic disease (ACD). Others include hemoglobinopathies. Sideroblastic anemia is easily differentiated by ring sideroblasts due to iron deposition and increased erythrocyte protoporphyrin level. Iron-deficiency anemia is ruled out by conducting iron studies (e.g., serum iron, total iron-binding capacity (TIBC)), serum ferritin, and transferrin saturation. Serum ferritin and transferrin saturation are low in iron deficiency. Additionally, RBCs are more likely hypochromic and less microcytic in IDA as compared to thalassemia. HPLC or Hb electrophoresis is used to differentiate other hemoglobinopathies from beta-thalassemia.[2][19]


Prior to 2000, beta-thalassemia major had a poor prognosis. The median survival was approximately 17 years in the US between 1965 to 1975. The median age was 12 years for the cohort born in Italy in the 1960s. But now, life expectancy has dramatically improved due to an interprofessional team approach among health care providers. Furthermore, the introduction of iron chelation therapy ICT (oral & injectable), awareness among patients and health care providers, management of complications, and utilization of standard techniques in the screening of blood products has contributed to improved outcomes. The life span of the affected patients in Palestine has increased from 7 to 8 years in 1996 to 19 to 20 years in 2015. Similarly, in the UK, the mortality rate significantly dropped to 4.7/1000 in the years 2000 to 2003 from 12.7/1000 in the years 1990 to 1999.[2][3][16]


Patients should be closely monitoring for potential complications owing to ineffective erythropoiesis, bone marrow (BM) overstimulation, and blood transfusion. The complications of the transfusion are of two types.

  1. Acute (e.g., severe allergic reactions, septic shock, hemolysis), and
  2. Chronic (e.g., diseases associated with iron overload (i.e., cardiomyopathy, endocrinopathy, and hepatotoxicity), alloimmunization, and transfusion-related infections.

Transfusion-related Complications

Iron overload: It is the primary chronic complication associated with long-term RBC transfusion in patients with beta-thalassemia. Transfused RBCs contain the iron load. Iron accumulates over time, and when the body's excess iron eliminating function is overwhelmed, iron starts depositing in various organs, commonly the heart, pancreas, liver, and brain. Cardiac failure secondary to cardiac IO is the leading cause of death in patients with TDT. Usually, the patient dies at a young age (<20) if not promptly addressed.

Iron overload (IO) in the liver results in liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma. Furthermore, the deposition of iron leads to diabetes, hypogonadism, hypothyroidism, and hypoparathyroidism secondary to pituitary gland disruption. Also, it can manifest as bronze skin, growth, and developmental delay. Therefore, ICT is essential in preventing these complications.

Alloimmunizations: It is the production of antibodies against specific RBC antigens or alloantigen (e.g., ABO, Rh, C, c, E, e, D, and Kell antigens) resulting from chronic transfusion. As per the international consensus recommendation, donated blood should be screened and crossmatched, and patients with thalassemia should receive antigen-compatible blood to avoid alloimmunization.

Transfusion-related infections: Viral, bacterial, and parasitic infections are common transfusion-related infections. Donated blood should be screened for HBV, HCV, and HIV as per World Health Organization (WHO) and Thalassemia International Federation (TIF) guidelines. Screening for endemic infections is also recommended in some countries.

Thrombosis/hypercoagulable state: Hypercoagulability is seen in patients with beta-thalassemia major (BTM) and beta-thalassemia intermedia (BTI) who are either poorly transfused, non-transfused, and splenectomized individuals.

Others include: Transfusion-related acute lung injury (TRALI), febrile non-hemolytic transfusion reaction, and delayed hemolytic transfusion reactions.[2][3][15][16]

Deterrence and Patient Education

The knowledge about beta-thalassemia (BT) is limited overall, especially in developing countries. Considering the chronic treatment, patients with BT need regular psychosocial support. Healthcare workers should provide available resources in the form of pamphlets, booklets, lectures, and videos to both patients and caregivers.

Due to the preventable nature of this disease in offspring by pre-marital or intrauterine screening, countries should focus on promoting community education widely to reduce BTM cases. Both the parents and the patients should be made aware of the disease inheritance pattern and the risk associated with it in subsequent pregnancies. They should be offered prenatal screening and genetic counseling. In Iran and Bahrain, the implementation of standard premarital screening in a locality significantly reduced the incidence of affected newborn babies.[20][21]

Enhancing Healthcare Team Outcomes

To enhance patient-centered care, a smooth flow of communication is required between the interprofessional team and patients. Several strategies need to be put into practice to improve patients outcomes.

  1. Patient-reported outcomes. It provides patients insights into the problem, quality of life, goals of care, and social support. Afterward, patient-reported outcomes need to be incorporated into health care.
  2. Shared decision making.
  3. Prioritize patient-centered discussion.
  4. Monitoring the general health and wellbeing of the patients.
  5. Encouraging patient engagement.

Health care workers can exchange vital information with the patient about chelation therapy and address their concerns to reduce tension and to reinforce the positive behavior of living a normal life.[22][23]



Cavazzana M, Antoniani C, Miccio A. Gene Therapy for β-Hemoglobinopathies. Molecular therapy : the journal of the American Society of Gene Therapy. 2017 May 3:25(5):1142-1154. doi: 10.1016/j.ymthe.2017.03.024. Epub 2017 Apr 1     [PubMed PMID: 28377044]


Needs T, Gonzalez-Mosquera LF, Lynch DT. Beta Thalassemia. StatPearls. 2023 Jan:():     [PubMed PMID: 30285376]


Cunningham MJ. Update on thalassemia: clinical care and complications. Pediatric clinics of North America. 2008 Apr:55(2):447-60, ix. doi: 10.1016/j.pcl.2008.02.002. Epub     [PubMed PMID: 18381095]


Viprakasit V, Ekwattanakit S. Clinical Classification, Screening and Diagnosis for Thalassemia. Hematology/oncology clinics of North America. 2018 Apr:32(2):193-211. doi: 10.1016/j.hoc.2017.11.006. Epub     [PubMed PMID: 29458726]


Cao A, Galanello R. Beta-thalassemia. Genetics in medicine : official journal of the American College of Medical Genetics. 2010 Feb:12(2):61-76. doi: 10.1097/GIM.0b013e3181cd68ed. Epub     [PubMed PMID: 20098328]


Sayani FA, Kwiatkowski JL. Increasing prevalence of thalassemia in America: Implications for primary care. Annals of medicine. 2015:47(7):592-604. doi: 10.3109/07853890.2015.1091942. Epub 2015 Nov 5     [PubMed PMID: 26541064]


Rahimi Z. Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran. BioMed research international. 2013:2013():803487. doi: 10.1155/2013/803487. Epub 2013 Jun 18     [PubMed PMID: 23853772]


Venugopal A, Chandran M, Eruppakotte N, Kizhakkillach S, Breezevilla SC, Vellingiri B. Monogenic diseases in India. Mutation research. Reviews in mutation research. 2018 Apr-Jun:776():23-31. doi: 10.1016/j.mrrev.2018.03.003. Epub 2018 Mar 17     [PubMed PMID: 29807575]


Yılmaz S. The Spectrum of β-Thalassemia Mutations in Siirt Province, Southeastern Turkey. Hemoglobin. 2019 May:43(3):174-181. doi: 10.1080/03630269.2019.1647852. Epub 2019 Aug 14     [PubMed PMID: 31411089]


Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, Arifuzzaman M, Razzaque MA, Alam R, Aziz S, Khatun H, Rahim A, Morshed M. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet journal of rare diseases. 2017 May 18:12(1):93. doi: 10.1186/s13023-017-0643-z. Epub 2017 May 18     [PubMed PMID: 28521805]


Ribeil JA, Arlet JB, Dussiot M, Moura IC, Courtois G, Hermine O. Ineffective erythropoiesis in β -thalassemia. TheScientificWorldJournal. 2013:2013():394295. doi: 10.1155/2013/394295. Epub 2013 Mar 28     [PubMed PMID: 23606813]


Fibach E, Dana M. Oxidative Stress in β-Thalassemia. Molecular diagnosis & therapy. 2019 Apr:23(2):245-261. doi: 10.1007/s40291-018-0373-5. Epub     [PubMed PMID: 30484264]


Origa R. β-Thalassemia. Genetics in medicine : official journal of the American College of Medical Genetics. 2017 Jun:19(6):609-619. doi: 10.1038/gim.2016.173. Epub 2016 Nov 3     [PubMed PMID: 27811859]


Javid B, Said-Al-Naief N. Craniofacial manifestations of β-thalassemia major. Oral surgery, oral medicine, oral pathology and oral radiology. 2015 Jan:119(1):e33-40. doi: 10.1016/j.oooo.2014.08.020. Epub 2014 Sep 16     [PubMed PMID: 25442247]

Level 3 (low-level) evidence


Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatric radiology. 2007 Dec:37(12):1191-200; quiz 1308-9     [PubMed PMID: 17710390]


Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood reviews. 2019 Sep:37():100588. doi: 10.1016/j.blre.2019.100588. Epub 2019 Jul 6     [PubMed PMID: 31324412]


Lal A, Bansal D. Thalassemia: Common Clinical Queries in Management. Indian journal of pediatrics. 2020 Jan:87(1):75-81. doi: 10.1007/s12098-019-03065-5. Epub 2019 Oct 16     [PubMed PMID: 31620986]


Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia - an update. F1000Research. 2017:6():2156. doi: 10.12688/f1000research.12688.1. Epub 2017 Dec 20     [PubMed PMID: 29333256]


Urrechaga E, Hoffmann JJ, Izquierdo S, Escanero JF. Differential diagnosis of microcytic anemia: the role of microcytic and hypochromic erythrocytes. International journal of laboratory hematology. 2015 Jun:37(3):334-40. doi: 10.1111/ijlh.12290. Epub 2014 Sep 2     [PubMed PMID: 25181647]


Dehkordi AH, Heydarnejad MS. Effect of booklet and combined method on parents' awareness of children with beta-thalassemia major disorder. JPMA. The Journal of the Pakistan Medical Association. 2008 Sep:58(9):485-7     [PubMed PMID: 18846795]


Widayanti CG, Ediati A, Tamam M, Faradz SM, Sistermans EA, Plass AM. Feasibility of preconception screening for thalassaemia in Indonesia: exploring the opinion of Javanese mothers. Ethnicity & health. 2011 Aug-Oct:16(4-5):483-99. doi: 10.1080/13557858.2011.564607. Epub     [PubMed PMID: 21797731]

Level 2 (mid-level) evidence


Lavallee DC, Chenok KE, Love RM, Petersen C, Holve E, Segal CD, Franklin PD. Incorporating Patient-Reported Outcomes Into Health Care To Engage Patients And Enhance Care. Health affairs (Project Hope). 2016 Apr:35(4):575-82. doi: 10.1377/hlthaff.2015.1362. Epub     [PubMed PMID: 27044954]


Abu Samra O, Auda W, Kamhawy H, Al-Tonbary Y. Impact of educational programme regarding chelation therapy on the quality of life for B-thalassemia major children. Hematology (Amsterdam, Netherlands). 2015 Jun:20(5):297-303. doi: 10.1179/1607845414Y.0000000197. Epub 2014 Sep 2     [PubMed PMID: 25181014]

Level 2 (mid-level) evidence